Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 6/2017

01-12-2017 | Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Skeletal muscle alterations in HFrEF vs. HFpEF

Authors: Volker Adams, Axel Linke, Ephraim Winzer

Published in: Current Heart Failure Reports | Issue 6/2017

Login to get access

Abstract

Purpose of review

Severe exercise intolerance and early fatigue are hallmarks of heart failure patients either with a reduced (HFrEF) or a still preserved (HFpEF) ejection fraction. This review, therefore, will provide a contemporary summary of the alterations currently known to occur in the skeletal muscles of both HFrEF and HFpEF, and provide some further directions that will be required if we want to improve our current understanding of this area.

Recent findings

Skeletal muscle alterations are well documented for over 20 years in HFrEF, and during the recent years also data are presented that in HFpEF muscular alterations are present. Alterations are ranging from a shift in fiber type and capillarization to an induction of atrophy and modulation of mitochondrial energy supply. In general, the molecular alterations are more severe in the skeletal muscle of HFrEF when compared to HFpEF.

Summary

The alterations occurring in the skeletal muscle at the molecular level may contribute to exercise intolerance in HFrEF and HFpEF. Nevertheless, the knowledge of changes in the skeletal muscle of HFpEF is still sparsely available and more studies in this HF cohort are clearly warranted.
Literature
1.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146.PubMedPubMedCentralCrossRef
2.
Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J. 2004;147:354–60.PubMedCrossRef
3.
Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. New England Journal of Medicine. 2006;355:260–9.PubMedCrossRef
4.
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017 in press.
5.
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European Heart Journal. 2012;33:1750–7.CrossRef
6.
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine. 2008;359:2456–67.PubMedCrossRef
7.
Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010;3:477–85.PubMedPubMedCentralCrossRef
8.
Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–91.PubMedCrossRef
9.
Kinugawa S, Tsutsui H, Ide T, Nakamura R, Arimura K, Egashira K, et al. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc Res. 1999;43:157–64.PubMedCrossRef
10.
Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.PubMedCrossRef
11.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.PubMedCrossRef
12.
Kondamudi N, Haykowsky M, Forman DE, Berry J, Pandey A. Exercise training for prevention and treatment of heart failure. Prog Cardiovasc Dis. 2017;60:115–20.PubMedCrossRef
13.
Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, et al. Exercise training in patients with heart failure and preserved ejection fraction: a meta-analysis of randomized control trials. Circ Heart Fail. 2015;8:33–40.PubMedCrossRef
14.
Maskin CS, Forman R, Sonnenblick EH, Frishman WH, LeJemtel TH. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. Am J Cardiol. 1983;51:177–82.PubMedCrossRef
15.
Stevenson LW, Sietsema K, Tillisch JH, Lem V, Walden J, Kobashigawa JA, et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation. 1990;81:78–85.PubMedCrossRef
16.
• Weiss K, Schär M, Panjrath GS, Zhang Y, Sharma K, Bottomley PA, et al. Fatigability, exercise intolerance, and abnormal skeletal muscle energetics in heart failure. Circ Heart Fail. 2017;10:e004129. Recent study using magnetic resonance spectroscopy measurement during exercise to determine high energy phosphates in HFrEF, HFpEf, and healthy controls PubMedCrossRef
17.
•• Seiler M, Bowen TS, Rolim N, Dieterlen MT, Werner S, Hoshi T et al. Skeletal muscle alterations are exacerbated in heart failure with reduced compared with preserved ejection fraction: mediated by circulating cytokines? Circ Heart Fail 2016:e003027. This is the first study directly comparing skeletal muscle alterations between HFrEF and HFpEF in animal models.
18.
Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3.PubMedCrossRef
19.
Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531–43.PubMedCrossRef
20.
Coirault C, Guellich A, Barbry T, Samuel JL, Riou B, Lecarpentier Y. Oxidative stress of myosin contributes to skeletal muscle dysfunction in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2007;292:H1009–17.PubMedCrossRef
21.
Attaix D, Ventadour S, Codran A, Bechet D, Taillandier D, Combaret L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem. 2005;41:173–86.PubMedCrossRef
22.
Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2015;6:197–207.PubMedPubMedCentralCrossRef
23.
Murton AJ, Constantin D, Greenhaff PL. The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy. Biochim Biophys Acta. 2008;1782:730–43.PubMedCrossRef
24.
Carmeli E, Aizenbud D, Rom O. How do skeletal muscles die? An overview. Adv Exp Med Biol. 2015;861:99–111.PubMedCrossRef
25.
26.
Rodriguez J, Vernus B, Chelh I, Cassar-Malek I, Gabillard JC, Hadj Sassi A, et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci. 2014;71:4361–71.PubMedCrossRef
27.
Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013;280:4294–314.PubMedCrossRef
28.
Bodine SC, Latres E, Baumhueter S, Lai VKM, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.PubMedCrossRef
29.
Clavel S, Coldefy AS, Kurkdjian E, Salles J, Margarites I, Derijard B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat tibialis anterior muscle. Mech Ageing Dev. 2006;127:794–801.PubMedCrossRef
30.
Gielen S, Sandri M, Kozarez I, Kratsch J, Teupser D, Thiery J, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the Randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging (LEICA) Catabolism Study. Circulation. 2012;125:2716–27.PubMedCrossRef
31.
Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001;98:14440–5.PubMedPubMedCentralCrossRef
32.
Lang CH, Huber D, Frost RA. Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. Am J Physiol Regul Integr Comp Physiol. 2007;292:R328–36.PubMedCrossRef
33.
Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem. 2002;277:49831–40.PubMedCrossRef
34.
Crispo M, Mulet AP, Tesson L, Barrera N, Cuadro F, dos Santos-Neto PC, et al. Efficient generation of myostatin knock-out sheep using CRISPR/Cas9 technology and microinjection into zygotes. PLoS One. 2015;10:e0136690.PubMedPubMedCentralCrossRef
35.
McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature. 1997;387:83–90.PubMedCrossRef
36.
Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J. 2008;22:477–87.PubMedCrossRef
37.
Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. New England Journal of Medicine. 2004;350:2682–8.PubMedCrossRef
38.
Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195–200.PubMedCrossRef
39.
Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34:512–9.PubMedCrossRef
40.
Anker S, Clark AL, Kemp M, Salsbury C, Teixeira MM, Hellewell PG, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 1997;30:997–1001.PubMedCrossRef
41.
Mancini D, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85:1364–73.PubMedCrossRef
42.
Levine B, Kalman J, Mayer L, Fillit HM, Packer MP. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New England Journal of Medicine. 1990;323:236–41.PubMedCrossRef
43.
Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–34.PubMedCrossRef
44.
Adams V, Linke A, Gielen S, Erbs S, Hambrecht R, Schuler G. Modulation of Murf-1 and MAFbx expression in the myocardium by physical exercise training. Eur J Cardiovasc Prev Rehabil. 2008;15:293–9.PubMedCrossRef
45.
Adams V, Linke A, Wisloff U, Döring C, Erbs S, Kränkel N, et al. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res. 2007;73:120–9.PubMedCrossRef
46.
Conraads V, Hoymans VY, Vrints CJ. Heart failure and cachexia: insights offered from molecular biology. Front Biosci. 2008;13:325–35.PubMedCrossRef
47.
Forman DE, Daniels KM, Cahalin LP, Zavin A, Allsup K, Cao P, et al. Analysis of skeletal muscle gene expression patterns and the impact of functional capacity in patients with systolic heart failure. J Card Fail. 2014;20:422–30.PubMedPubMedCentralCrossRef
48.
Mangner N, Weikert B, Bowen TS, Sandri M, Höllriegel R, Erbs S, et al. Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm. J Cachexia Sarcopenia Muscle. 2015;6:381–90.PubMedPubMedCentralCrossRef
49.
Bacurau AVN, Jannig PR, de Moraes WMAM, Cunha TF, Medeiros A, Barberi L, et al. Akt/mTOR pathway contributes to skeletal muscle anti-atrophic effect of aerobic exercise training in heart failure mice. Int J Cardiol. 2016;214:137–47.PubMedCrossRef
50.
Barreiro E, Puig-Vilanova E, Marin-Corral J, Chacon-Cabrera A, Salazar-Degracia A, Mateu X, et al. Therapeutic approaches in mitochondrial dysfunction, proteolysis, and structural alterations of diaphragm and gastrocnemius in rats with chronic heart failure. J Cell Physiol. 2015;231:1495–513.PubMedCrossRef
51.
Niebauer J, Pflaum CD, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, et al. Deficient insulin-like growth factor 1 in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol. 1998;32:393–7.PubMedCrossRef
52.
Hambrecht R, Schulze PC, Gielen S, Linke A, Mobius-Winkler S, Yu J, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2002;39:1175–81.PubMedCrossRef
53.
Schulze PC, Gielen S, Adams V, Linke A, Möbius-Winkler S, Erbs S, et al. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure. Basic Res Cardiol. 2003;98:267–74.PubMedCrossRef
54.
Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left ventricular dysfunction. Circ Res. 2005;97:418–26.PubMedCrossRef
55.
Lenk K, Erbs S, Höllriegel R, Beck E, Linke A, Gielen S, et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur J Prev Cardiol. 2012;19:404–11.PubMedCrossRef
56.
Lenk K, Schur R, Linke A, Erbs S, Matsumoto Y, Adams V, et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail. 2009;11:342–8.PubMedCrossRef
57.
•• Haykowsky MJ, Brubaker PH, Morgan TM, Kritchevsky S, Eggebeen J, Kitzman DW. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J Gerontol A Biol Sci Med Sci. 2013;68:968–75. An excellent clinical study abnormalities showing that alterations in skeletal muscle perfusion and/or metabolism contribute to the severe exercise intolerance in older HFPEF patients PubMedPubMedCentralCrossRef
58.
Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6–19.PubMedCrossRef
59.
Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113:1211–6.PubMedPubMedCentralCrossRef
60.
Bowen TS, Brauer D, Rolim N, Bakkerud F, Kricke A, Ormbostad AM et al. Exercise training reveals inflexibility of teh diaphragm in an obesity-driven HFpEF animal model. J Am Heart Assoc 2017;in press.
61.
Conceicao G, Heinonen I, Lourenco AP, Duncker DJ, Falcao-Pires I. Animal models of heart failure with preserved ejection fraction. Netherlands Heart Journal. 2016;24:275–86.PubMedPubMedCentralCrossRef
62.
• Bowen TS, Rolim NPL, Fischer T, Baekkerud FH, Medeiros A, Werner S, et al. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle. Eur J Heart Fail. 2015;17:263–72. This was the first study using a validated HFpEF animal model to investigate mitochondrial as well as functional alterations in skeletal and diaphragmatic muscle PubMedCrossRef
63.
Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2011;91:1447–531.PubMedCrossRef
64.
Mancini DM, Coyle E, Coggan A, Beltz J, Ferraro N, Montain S, et al. Contribution of intrinsic skeletal muscle changes to 31-P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation. 1989;80:1338–46.PubMedCrossRef
65.
Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation. 1990;81:518–27.PubMedCrossRef
66.
Drexler H, Riede U, Münzel T, König H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85:1751–9.PubMedCrossRef
67.
Schaufelberger M, Eriksson BO, Grimby G, Held P, Swedberg K. Skeletal muscle fiber composition and capillarization in patients with chronic heart failure: relation to exercise capacity and central hemodynamics. J Card Fail. 1995;1:267–72.PubMedCrossRef
68.
Okada K, Naito AT, Higo T, Nakagawa A, Shibamoto M, Sakai T, et al. Wnt/ß-catenin signaling contributes to skeletal myopathy in heart failure via direct interaction with Forkhead Box O. Circ Heart Fail. 2015;8:799–808.PubMedCrossRef
69.
Delp MD, Duan C, Mattson JP, Musch TI. Changes in skeletal muscle biochemistry and histology relative to fiber type in rats with heart failure. J Appl Physiol. 1997;83:1291–9.PubMed
70.
Williams AD, Selig S, Hare DL, Hayes A, Krum H, Patterson J, et al. Reduced exercise tolerance in CHF may be related to factors other than impaired skeletal muscle oxidative capacity. J Card Fail. 2004;10:141–8.PubMedCrossRef
71.
Hirai DM, Musch TI, Poole DC. Exercise training in chronic heart failure: improving skeletal muscle O2 transport and utilization. Am J Physiol Heart Circ Physiol. 2015;309:H1419–39.PubMedPubMedCentralCrossRef
72.
Howell S, Maarek JM, Fournier M, Sullivan K, Zhan WZ, Sieck GC. Congestive heart failure: differential adaptation of the diaphragm and latissimus dorsi. J Appl Physiol. 1995;79:389–97.PubMed
73.
Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2014;306:H1364–70.PubMedPubMedCentralCrossRef
74.
Tikunov B, Levine S, Mancini D. Chronic congestive heart failure elicts adaptations of endurance exercise in diaphragmatic muscle. Circulation. 1997;95:910–6.PubMedCrossRef
75.
76.
Wing SS, Lecker SH, Jagoe RT. Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. Crit Rev Clin Lab Sci. 2011;48:49–70.PubMedCrossRef
77.
Rabinovich RA, Vilaro J. Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2010;16:123–33.PubMedPubMedCentralCrossRef
78.
Ushmorov A, Hack V, Dröge W. Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia. Cancer Res. 1999;59:3527–34.PubMed
79.
De Sousa E, Veksler V, Bigard X, Mateo P, Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Ciculation. 2000;102:1847–53.CrossRef
80.
Mettauer B, Zoll J, Sanchez H, Lampert E, Ribera F, Veksler V, et al. Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects. JACC. 2001;4:947–54.CrossRef
81.
82.
Wilson JR, Fink L, Maris J, Ferraro N, Power-Vanwart J, Eleff S, et al. Evaluation of energy metabolism in skeletal muscle in patients with heart failure with gated phosphorus-31 nuclear magnetic resonance. Circulation. 1985;71:57–62.PubMedCrossRef
83.
Wiener DH, Fink LI, Maris J, Jones RA, Chance B, Wilson JR. Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow. Circulation. 1986;73:1127–36.PubMedCrossRef
84.
Hambrecht R, Adams V, Gielen S, Linke A, Möbius-Winkler S, Yu J, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999;33:174–9.PubMedCrossRef
85.
Marin-Garcia J, Goldenthal MJ, Moe GW. Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc Res. 2001;52:103–10.PubMedCrossRef
86.
Schrepper A, Schwarzer M, Schöpe M, Amorim PA, Doenst T. Biphasic response of skeletal muscle mitochondria to chronic cardiac pressure overload—role of respiratory chain complex activity. J Mol Cell Cardiol. 2012;52:125–35.PubMedCrossRef
87.
Mettauer B, Zoll J, Garnier A, Ventura-Clapier R. Heart failure: a model of cardiac and skeletal muscle energetic failure. Pflugers Arch - Eur J Physiol. 2006;452:653–66.CrossRef
88.
Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B, et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:1296–304.PubMedPubMedCentralCrossRef
89.
• Molina AJA, Bharadwaj MS, Van Horn C, Nicklas BJ, Lyles MF, Eggebeen J, et al. Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance. JACC Heart Fail. 2016;4:636–45. The first study in human skeletal muscle biopsies showing that muscle oxidative capacity, mitochondrial content, and mitochondrial fusion are abnormal in older patients with HFpEF PubMedPubMedCentralCrossRef
90.
Twig G, Hyde B, Shirihai OS. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta. 2008;1777:1092–7.PubMedCrossRef
91.
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–11.PubMedCrossRef
92.
Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction. Circulation. 2003;107:1486–91.PubMedCrossRef
93.
Li XQ, Cao W, Li T, Zeng AG, Hao LL, Zhang XN, et al. Amlodipine inhibits TNF-a production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. Int Immunopharmacol. 2009;9:1032–41.PubMedCrossRef
94.
Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–42.PubMedCrossRef
95.
96.
Torre-Amione G, Kapadia SR, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–6.PubMedCrossRef
97.
Marti CN, Khan H, Mann DL, Georgiopoulou VV, Bibbins-Domingo K, Harris T, et al. Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study. Circ Heart Fail. 2014;7:5–11.PubMedCrossRef
98.
Batista J, Rosa JC, Lopes RD, Lira FS, Martins J, Yamashita AS, et al. Exercise training changes IL-10/TNF-[alpha] ratio in the skeletal muscle of post-MI rats. Cytokine. 2010;49:102–8.PubMedCrossRef
99.
100.
Lang CH, Frost RA, Nairin AC, MacLean DA, Vary TC. TNF-a impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab. 2002;282:E336–47.PubMedCrossRef
101.
Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha. Am j Respir Crit care Med. 2002;166:479–84.PubMedCrossRef
102.
Gielen S, Adams V, Möbius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003;42:861–8.PubMedCrossRef
103.
Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) Study. J Am Coll Cardiol. 2010;55:2129–37.PubMedPubMedCentralCrossRef
104.
Santhanakrishnan R, Chong JPC, Ng TP, Ling LH, Sim D, Toh GL, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2012;14:1338–47.PubMedCrossRef
Metadata
Title
Skeletal muscle alterations in HFrEF vs. HFpEF
Authors
Volker Adams
Axel Linke
Ephraim Winzer
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 6/2017
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-017-0361-9

Other articles of this Issue 6/2017

Current Heart Failure Reports 6/2017 Go to the issue

Comorbidities of Heart Failure (C Angermann and F Edelmann, Section Editors)

Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus

Genetics of Heart Failure (K Adams, Section Editor)

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure

Pharmacologic Therapy (W H W Tang, Section Editor)

Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices

Prevention of Heart Failure (M. St. John Sutton, Section Editor)

Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond

Pharmacologic Therapy (W H W Tang, Section Editor)

MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential

Prevention of Heart Failure (M Sutton, Section Editor)

Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits